Copyright by ICR Publishers 2014
|
|
- Edwina Marcia Harrington
- 5 years ago
- Views:
Transcription
1 Comprehensive Hemodynamic Performance and Frequency of Patient-Prosthesis Mismatch of the St. Jude Medical Trifecta Bioprosthetic Aortic Valve Ajay Yadlapati 1, Jimmy Diep 3, Mary-Jo Barnes 2, Tristan Grogan 4, Daniel M. Bethencourt 2, Gabriel Vorobiof 1 1 Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 2 Long Beach Memorial Medical Center, Heart & Vascular Institute, Long Beach, CA, 3 Department of Medicine, Division of Cardiology, University of California Irvine, Irvine, CA, 4 Department of Medicine, Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA Background and aim of the study: The study aim was to evaluate the performance of a new stented pericardial bioprosthesis, the Trifecta (St. Jude Medical, St. Paul, MN, USA), for aortic valve replacement (AVR) with respect to valvular hemodynamics and frequency of patient-prosthesis mismatch (PPM). PPM has been reported in a wide range of bioprosthetic valves following AVR, and has been associated with multiple adverse outcomes. It was hypothesized that the Trifecta aortic valve would have superior hemodynamics and an acceptable incidence of PPM following AVR. Methods: A prospective cohort study was performed between January 2010 and May 2012, following 75 patients (mean age 71.9 ± 11.1 years) who had undergone AVR with a Trifecta valve for aortic stenosis (88%) or regurgitation (12%) at the authors institutions. Intraoperative three-dimensional and Doppler transesophageal echocardiography were used to evaluate hemodynamic variables before and after AVR, as well as pre-discharge. Results: Echocardiographic evaluation showed a preoperative average mean gradient (MG) of 40.6 ± 21.6 mmhg, an average peak gradient (PG) of 72.1 ± 19.4 mmhg, and an average effective orifice area index (EOAI) of 0.39 ± 0.20 cm 2 /m 2. Postoperative mean pressure gradient measurements showed a postoperative average MG of 8.76 ± 3.75 mmhg (p <0.001), an average PG of 19.4 ± 8.6 mmhg (p <0.001), and EOAI of 1.09 ± 0.36 cm 2 /m 2 (p <0.001), which demonstrated a significantly improved hemodynamic performance across all valve sizes. Postoperative MG versus measured EOAI demonstrated a fairly linear relationship (R2 = ), rather than a rapid increase in MG with EOAI < 0.85 and < 0.65, as was seen with previous valve designs. Severe PPM (defined as EOAI 0.65 cm 2 /m 2 ) was found in four patients (6%), while moderate PPM (EOAI >0.65 and <0.85 cm 2 /m 2 ) was seen in 11 patients (16%). Conclusion: The Trifecta pericardial valve demonstrated excellent hemodynamic performance at all valve sizes, and resulted in very low postoperative transvalvular pressure gradients and PPM, without the need for aortic root enlargement. The Journal of Heart Valve Disease 2014;23: Each year, aortic valve replacement (AVR) is performed in almost 50,000 patients in the United States (1). Prosthesis-patient mismatch (PPM) occurs when the Presented at the Valves in the Heart of the Big Apple Conference, 12th April 2012, New York, NY, USA, and as a poster at the American College of Cardiology 62nd Annual Scientific Session and ACC-i2 with TCT, 11th March 2013, San Francisco, California, and the American College of Physicians Annual Meeting, 10th April 2013, San Francisco, California, USA Address for correspondence: Gabriel Vorobiof MD, FACC, David Geffen School of Medicine at UCLA, Division of Cardiology & UCLA Cardiovascular Center, 100 UCLA Medical Plaza, Suite 630, Los Angeles, CA 90095, USA gvorobiof@mednet.ucla.edu effective orifice area (EOA) of a normally functioning aortic prosthesis is too small in relation to the patient s cardiac output requirements, resulting in high transvalvular pressure gradients. Moderate and severe PPM - defined as an indexed EOA (EOAI) 0.85 cm 2 /m 2 - appears to be variably present following AVR, with reported incidence rates ranging from 30.7% to 53.7% (2-7). PPM presents the left ventricle with a higher resistance to overcome, and can be demonstrated by high transvalvular pressure gradients on echocardiography. This increased afterload seems to underlie the reason behind a slower regression of left ventricular mass and an adverse overall prognosis in patients with PPM (8-10). Copyright by ICR Publishers 2014
2 Performance of the SJM Trifecta bioprosthetic valve 517 Over the past half-century, the manufacture of artificial heart valves has undergone tremendous changes, with more than 80 models having been introduced since In 2011, a new-generation pericardial tissue valve, the Trifecta (St. Jude Medical, St. Paul, MN, USA), was introduced and approved by the FDA for the use in AVR (11). The Trifecta valve is a three-leaflet stented pericardial valve designed for supra-annular placement in the aortic position. The stent, excluding the true supra-annular sewing cuff, is covered with porcine pericardial tissue and the valve leaflets are manufactured using bovine pericardial tissue, which is wrapped around the intrinsically distensible titanium stent, rather than mounted inside. Overall, the design is aimed at maximizing valve hemodynamics while minimizing leaflet stresses (12). Previous studies with the Trifecta valve have suggested that hemodynamic performance, EOAs and mean transvalvular pressure gradients may be improved, especially in patients requiring small bioprosthetic valve sizes (13). Thus, it was hypothesized that the short-term hemodynamic performance of the Trifecta stented pericardial tissue bioprosthesis for AVR would have superior hemodynamics and an acceptable incidence of PPM. Clinical material and methods Study design and population A prospective, non-controlled cohort study was performed between January 2010 and May 2012, following 75 patients (24 women, 51 men; mean age 71.9 ± 11.1 years; range: 44 to 87 years), who had undergone AVR for aortic stenosis (88%) or regurgitation (12%) with a Trifecta aortic valve at the authors institutions. The patient baseline demographics are listed in Table I. Table I: Baseline demographics of the patients. Variable Value Age (years) * 71.9 ± 11.1 Body surface area (m 2 ) * 1.92 ± 0.23 Male gender (%) 68.0 Coronary artery disease (%) 36.0 Atrial fibrillation (%) 42.7 Hypertension (%) 92.0 Hyperlipidemia (%) 80.0 COPD (%) 6.7 Asthma (%) 9.3 Cerebrovascular accident (%) 18.7 End-stage renal disease (%) 4.0 Congestive heart failure (%) 30.7 * Values are mean ± SD. COPD: Chronic obstructive pulmonary disease. Intraoperative two- and three-dimensional and Doppler transesophageal echocardiography (TEE) were used to evaluate hemodynamic variables before and after AVR in the operating room, as well as predischarge (mean 5 ± 2 days). Eligibility criteria included all patients who received the Trifecta valve between January 2010 and May A bioprosthesis was selected if the expected durability of the valve was greater than the patient s expected lifetime. Five cases were excluded from analysis due to postoperative left ventricular outflow tract (LVOT) obstruction (n = 3), the use of Trifecta for an isolated pulmonary valve replacement (n = 1), and an isolated tricuspid valve replacement (n = 1). Aortic root enlargement was not required in any of the patients. Surgical technique An anterior thoracotomy approach was used in all patients who underwent an isolated, primary AVR. The operative technique included a midline sternotomy in 50 patients (66%) and port access via a small anterior thoracotomy in 25 (33%). The prosthesis size was estimated according to the size of the aortic annulus on TEE, but the final size was determined using the manufacturer-supplied replica sizer. Prostheses were implanted using interrupted braided Dacron sutures reinforced with 3 7 mm Teflon felt pledgets placed below the aortic annulus. Aortic root enlargement at the non-coronary sinus was not employed in any of the patients. Patients who required additional procedures such as coronary artery bypass graft(s), redo-avr and AVR with root replacement underwent sternotomy rather than the minimally invasive anterior thoracotomy. These patients were not included in the study cohort. Echocardiographic variables Transthoracic echocardiography (TTE) and TEE were performed using Philips ie33 and Acuson Sequoia instruments. Two-dimensional and, when required, three-dimensional imaging were used to quantify all echocardiographic variables. A complete TTE examination was performed at baseline and before discharge by an experienced echocardiographer. Calculations of hemodynamic parameters were made according to the 2009 American Society of Echocardiography Guidelines Evaluation of Prosthetic Valves (14). All Doppler measurements were averaged over three cardiac cycles in patients with sinus rhythm, and over five cardiac cycles in those with atrial fibrillation. The LVOT diameter was measured immediately proximal to the prosthesis sewing ring to avoid flow acceleration within the lower portion of the prosthesis (14). The EOA was calculated using the
3 518 Performance of the SJM Trifecta bioprosthetic valve Table II: Hemodynamic performance of the Trifecta aortic valve: Preoperative versus postoperative data. Variable Preoperative Postoperative p-value * Mean gradient (mmhg) 40.6 ± ± 3.75 <0.001 Peak gradient (mmhg) 72.1 ± ± 8.6 <0.001 EOAI (cm 2 /m 2 ) 0.39 ± ± 0.36 <0.001 Velocity index (LVOT/AV) 0.19 ± ± 0.14 <0.001 by VTI Values are mean ± SD. * Paired t-test. AV: Aortic valve; EOAI: Effective orifice area index; LVOT: Left ventricular outflow tract; VTI: Velocity time integral. continuity equation (LVOT area velocity time integral (VTI) LVOT /VTI valve ), using echo-doppler. The EOAI was calculated using the EOA divided by the patient s body surface area (m 2 ); the BSA was calculated using the Dubois formula (15). The velocity index (VI, a dimensionless ratio) was defined as the ratio of the LVOT VTI divided by the aortic valve continuous-wave spectral Doppler VTI (14). Severe PPM was defined as EOAI <0.65 cm 2 /m 2, moderate PPM as EOAI cm 2 /m 2, and non-significant (i.e., mild or no PPM) as EOAI >0.85 cm 2 /m 2 (16). Statistical analysis Continuous and normally distributed data were reported as mean ± SD. Student s t-test, corrected for Bonferroni adjustment, was used for paired data testing. Transvalvular pressure gradients were performed as a point-to-point statistical analysis. A p-value <0.05 was considered to be statistically significant. All statistical analyses and plots were performed using R, version (R Foundation for Statistical Computing, Vienna, Austria) and IBM SPSS, version 19 (SPSS, Chicago, IL, USA). Results Echocardiographic evaluation showed a preoperative average mean gradient (MG) of 40.6 ± 21.6 mmhg, an average peak gradient (PG) of 72.1 ± 19.4 mmhg, an average EOA of 0.7 ± 0.3 cm 2, and an average EOAI of 0.4 ± 0.2 cm 2 /m 2. Postoperative measurements (Table II) showed a postoperative average MG of 8.76 ± 3.75 mmhg, an average PG of 19.4 ± 8.6 mmhg, and an EOAI of 1.09 ± 0.36 cm 2 /m 2, which demonstrated a significantly improved hemodynamic performance across all valve sizes (Table III; Fig. 1). The 21 mm (n = 28; 40%), 23 mm (n = 19; 27%) and 25 mm (n = 14; 20%) valves were most frequently utilized, and showed statistically significant improvements in Figure 1: St. Jude Medical Trifecta aortic valve. Preoperative and postoperative mean gradient and effective orifice area index (EOAI), by valve size. Figure 2: St. Jude Medical Trifecta aortic valve. Preoperative and postoperative mean gradient by valve size.
4 Performance of the SJM Trifecta bioprosthetic valve 519 Figure 3: St. Jude Medical Trifecta aortic valve. Preoperative and postoperative peak gradient by valve size. MG (Fig. 2), PG (Fig. 3), EOAI (Fig. 4), and also VI by VTI (Fig. 5). The 19 mm (n = 2; 3%), 27 mm (n = 6; 9%) and 29 mm (n = 1; 1%) valves comprised only nine cases (13%) within the study cohort. These prostheses showed similar improvements in hemodynamics, but the statistical significance was neutral given the small sample size for this subgroup. The postoperative MG versus measured EOAI (Fig. 6) showed a fairly linear relationship (R2 = ), rather than a rapid increase in MG with EOAI <0.85 and <0.65 cm 2 /m 2, as seen with previous valve designs (17). The MG remained low (<10 mmhg), regardless of valve size or measured EOAI. Severe PPM was found in four patients (6%), and moderate PPM in 11 patients (16%). The average postoperative MG in patients with moderate-to-severe PPM was 9.9 mmhg, and 9.1 mmhg in patients with EOAI >0.85 cm 2 /m 2. No aortic root enlargements were required. The expected versus achieved EOAIs are shown graphically in Figures 7 and 8. In the past, the valve manufacturers have attempted to simplify the implantation process by providing charts which include the expected EOAI for their prosthesis. A caveat with these charts is that the expected EOA data must truly be reliable; otherwise the chart can misguide the implanting surgeon (18). To help improve the predictive abilities of the expected EOAI, manufacturers also provide a replica sizer to help the surgeon better estimate which valve size to use. Achieved EOAIs were calculated measurements based on echocardiographic data. Figure 4: St. Jude Medical Trifecta aortic valve. Preoperative and postoperative EOAI by valve size. Figure 5: St. Jude Medical Trifecta aortic valve. Preoperative and postoperative velocity index by valve size.
5 520 Performance of the SJM Trifecta bioprosthetic valve Table III: Hemodynamic performance of the Trifecta aortic valve: Preoperative versus postoperative data, by valve size. Variable/ Preoperative * Postoperative * p-value # Valve size (mm) Mean gradient ± 7.1 (n = 2) 11.3 ± 6.0 (n = 2) ± 24.9 (n = 28) 10.6 ± 4.2 (n = 28) < ± 22.3 (n = 19) 8.2 ± 3.0 (n = 19) < ± 18.7 (n = 14) 8.4 ± 3.3 (n = 14) < ± 20.9 (n = 6) 6.2 ± 3.4 (n = 6) (n = 1) 5.0 (n = 1) - Peak gradient ± 5.7 (n = 2) 22.5 ± 9.2 (n = 2) ± 21.5 (n = 28) 36.9 ± 8.3 (n = 28) < ± 35.1 (n = 19) 21.0 ± 9.7 (n = 19) < ± 34.6 (n = 14) 17.6 ± 6.4 (n = 14) < ± 32.4 (n = 6) 12.1 ± 6.7 (n = 6) (n = 1) 10 (n = 1) - EOAI ± 0.07 (n = 2) 0.68 ± 0.03 (n = 2) ± 0.21 (n = 28) 1.03 ± 0.18 (n = 28) < ± 0.15 (n = 19) 0.92 ± 0.21 (n = 19) < ± 0.15 (n = 14) 1.33 ± 0.44 (n = 14) < ± 0.10 (n = 6) 1.33 ± 0.55 (n = 6) (n = 1) 1.40 (n = 1) - Velocity index (LVOT/AV) by VTI ± 0.01 (n = 2) 0.43 ± 0.07 (n = 2) ± 0.11 (n = 28) 0.60 ± 0.09 (n = 28) < ± 0.09 (n = 19) 0.57 ± 0.14 (n = 19) < ± 0.05 (n = 14) 0.60 ± 0.16 (n = 14) < ± 0.07 (n = 6) 0.70 ± 0.16 (n = 6) (n = 1) 0.39 (n = 1) - * Values are mean ± SD. # Paired t-test. AV: Aortic valve; EOAI: Effective orifice area index; LVOT: Left ventricular outflow tract; VTI: Velocity time integral. Figure 6: St. Jude Medical Trifecta aortic valve. Mean gradient versus effective orifice area index (EOAI). Figure 7: St. Jude Medical Trifecta aortic valve. Achieved effective orifice area index (EOAI) versus expected EOAI.
6 Performance of the SJM Trifecta bioprosthetic valve 521 Figure 8: St. Jude Medical Trifecta aortic valve. Frequency of achieved effective orifice area index (EOAI) versus expected EOAI. Discussion Over the past decade, several models of tissue heart valves have been introduced, the main rationale for using bioprosthetic valves being their low thrombogenicity such that anticoagulation will not be required per se. Consequently, these valves seem to be eminently suitable for patients with isolated aortic valve disease, who are in sinus rhythm and do not have any concomitant cardiomyopathy that would necessitate anticoagulation (5). Many improvements in bioprosthetic valve designs have been introduced over time. Optimizing hemodynamics to prevent PPM and improve durability revived the use of stentless bioprostheses during the early 1990s (6). Although stentless AVR required longer cross-clamp and cardiopulmonary bypass times, the postoperative outcomes were indeed favorable. In patients with a depressed left ventricular function, the operative outcomes were better in stentless valves owing to the larger orifice area when the full-root technique was applied to avoid PPM (19). Additionally, several studies demonstrated superior hemodynamics with almost no increase in MG under exercise with stentless valves compared to mechanical valves after AVR (20, 21). Although stentless bioprostheses were originally thought to replace stented biological valves due to a better hemodynamic performance and longer durability, many surgeons still use stented valves because they are easier to implant, especially when using a minimally invasive approach. Concerns regarding PPM can be addressed by augmenting the aortic root (22) or by replacing the aortic root along with the valve (23). Gulbins et al. (24) reported that less than 12% of all aortic valve prostheses implanted in Europe were stentless. This low proportion of stentless valves was attributed to similar hemodynamic performance and an easier implanting technique of new-generation bioprostheses such as the Carpentier- Edwards Perimount Magna valve. Stentless valves with an easier implantation technique may increase the market of stentless bioprostheses in the future (25). All prosthetic valves have an EOA which is smaller than that of the native human valve, and therefore will have some degree of PPM. Significant PPM is defined as an EOA that is too small in relation to the patient s body size (7), and results in high postoperative gradients. Pibarot and colleagues (16) described the use of EOAI to predict significant PPM for the aortic valve, using published EOA data supplied to the FDA by the valve manufacturers but divided by the patient s BSA; thus, they defined PPM as an EOAI 0.85 cm 2 /m 2 (15,26-28). This threshold was chosen because, at smaller EOAI-values, the transvalvular gradient showed a rapid increase. According to this definition, PPM can be divided into moderate PPM, with EOAI cm 2 /m 2 and severe PPM, with EOAI <0.65 cm 2 /m 2. In the present study, EOAI was measured directly in the operating room after implantation. Using the same threshold values, severe PPM was found in four patients (6%), and moderate PPM in 11 (16%). These data were consistent with the large multicenter data reported by Bavaria et al. (12), where the frequency for mild to moderate PPM was 23% and for severe PPM was 2%. The present data were also consistent with those of other investigators, who showed no evidence of severe PPM with the Trifecta valve in 200 patients (29). In addition to PPM, the Trifecta valve has also performed favorably with regards to hemodynamic performance during exercise, when compared to the Medtronic Freestyle aortic valve bioprosthesis (30). When compared to other supra-annular valves, the Trifecta valve revealed significantly higher aortic valve areas at the six-month follow up, although after multivariate covariance adjustment the type of prosthesis could not be identified as an independent factor influencing the mean pressure gradients or aortic valve area at the six-month follow up. Hence, further long-term data are required to fully evaluate the long-term performance of the Trifecta valve (31). Among patients undergoing AVR, PPM is a commonly encountered problem that leads to a worsened hemodynamic function, less regression of left ventricular hypertrophy (LVH), and more cardiac events with lower survival rates (12,16). It has also been shown that an incomplete regression of left ventricular mass and function after AVR is related to poor long-term survival (3). Conversely, an improved hemodynamic performance resulted in a faster left
7 522 Performance of the SJM Trifecta bioprosthetic valve ventricular mass reduction in patients with aortic stenosis and LVH (2). Hence, the minimization of postoperative PGs across the implanted valve is one of the most important goals of AVR. Postoperative PPM can be avoided through optimal prosthesis selection in the individual patient by calculating the EOAI prior to surgery. This is particularly important in patients with left ventricular dysfunction and/or severe LVH (7). This experience with the Trifecta valve, in a preliminary single-center study, demonstrated excellent immediate-term clinical and hemodynamic outcomes, though long-term outcomes will need to be assessed to help understand the hemodynamic performance over time. Whilst the excellent hemodynamic performance of the Trifecta valve resulted in impressively low rates of severe PPM, the plan is to continue the follow up at six and 12 months to evaluate the incidence of PPM and its effect on longterm outcome, as previously recommended (17). Study limitations The primary limitation was that the study involved only a moderate cohort size (n = 75) from a single institution. In addition, the EOAI data were obtained immediately after surgery and may have been influenced by factors such as changes in preload, afterload, and inotropy. All measurements, however, were repeated on TTE prior to discharge and showed no significant changes. Another limitation was that no comparison group was used; rather, historical rates of PPM were used. Finally, the relevance of these hemodynamic changes was not correlated with clinical events, although previous studies have shown severe PPM to be a poor prognostic marker and a valid surrogate for future adverse events. In conclusion, the Trifecta aortic valve bioprosthesis demonstrated excellent hemodynamic performance across all valve sizes, with low mean gradients and high velocity ratios indicating a low resistance to aortic valve outflow. This hemodynamic performance was maintained in patients with low EOAI (see Fig. 6). The transvalvular gradients remained low independent of the valve size, the measured EOAI, or the predicted EOAI. The Trifecta valve can be implanted with open or minimally invasive surgical approaches, as well as potentially minimizing the need for aortic root enlargement. However, confirmation of these preliminary results is required by performing longterm outcome studies. Acknowledgements Dr. Vorobiof is a consultant at St. Jude Medical and is on the Speakers Bureau for Lantheus Medical Imaging. Dr. Bethencourt is a consultant for Intuitive Surgical, St. Jude Medical, Edwards Lifesciences, and Medtronic. References 1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation 2005;111: Head SJ, Mokhles MM, Osnabrugge RL, et al. The impact of prosthesis-patient mismatch on longterm survival after aortic valve replacement: A systematic review and meta-analysis of 34 observational studies comprising patients with patient-years. Eur Heart J 2012;33: Hernandez-Vaquero D, Llosa JC, Diaz R, et al. Impact of patient-prosthesis mismatch on 30-day outcomes in young and middle-aged patients undergoing aortic valve replacement. J Cardiothorac Surg 2012;7:46 4. Van Linden A, Kempfert J, Blumenstein J, et al. Prosthesis-patient mismatch after transcatheter aortic valve implantation using the Edwards SAPIEN prosthesis. Thorac Cardiovasc Surg 2012;61: Jamieson WR, Ye J, Higgins J, et al. Effect of prosthesis-patient mismatch on long-term survival with aortic valve replacement: Assessment to 15 years. Ann Thorac Surg 2010;89:51-58; discussion Yottasurodom C, Namthaisong K, Porapakkham P, et al. Patient-prosthesis mismatch has no influence on in-hospital mortality after aortic valve replacement. J Med Assoc Thailand 2012;95 (Suppl.8):S64-S70 7. Rahimtoola SH. The problem of valve prosthesispatient mismatch. Circulation 1978;58: Tasca G, Brunelli F, Cirillo M, et al. Impact of valve prosthesis-patient mismatch on left ventricular mass regression following aortic valve replacement. Ann Thorac Surg 2005;79: Ruel M, Rubens FD, Masters RG, et al. Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves. J Thorac Cardiovasc Surg 2004;127: Ruel M, Al-Faleh H, Kulik A, Chan KL, Mesana TG, Burwash IG. Prosthesis-patient mismatch after aortic valve replacement predominantly affects patients with preexisting left ventricular dysfunction: Effect on survival, freedom from heart failure, and left ventricular mass regression. J Thorac Cardiovasc Surg 2006;131: St. Jude Medical. Trifecta Valve P-MAASoSaED, P100029, Bavaria JE, Desai ND, Cheung A, et al. The St. Jude Medical Trifecta aortic pericardial valve: Results
8 Performance of the SJM Trifecta bioprosthetic valve 523 from a global, multicenter, prospective clinical study. J Thorac Cardiovasc Surg 2014;147: Vorobiof G, Diep J, Barnes M-J, Bethencourt DM. Comprehensive hemodynamic performance comparison and frequency of patient prosthesis mismatch between the St. Jude Medical Epic and the Trifecta bioprosthetic aortic valves. Valves in the Heart of the Big Apple Conference, 12th April 2012, New York, NY, pp Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: A report from the American Society of Echocardiography s Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009;22: DuBois D. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17: Pibarot P, Honos GN, Durand LG, Dumesnil JG. The effect of prosthesis-patient mismatch on aortic bioprosthetic valve hemodynamic performance and patient clinical status. Can J Cardiol 1996;12: Daneshvar SA, Rahimtoola SH. Valve prosthesispatient mismatch (VP-PM): A long-term perspective. J Am Coll Cardiol 2012;60: House CM, Nelson WB, Kroshus TJ, Dahiya R, Pibarot P. Manufacturer-provided effective orifice area index charts and the prevention of prosthesispatient mismatch. 2012;21: Gulbins H, Reichenspurner H. Which patients benefit from stentless aortic valve replacement? Ann Thorac Surg 2009;88: De Paulis R, Sommariva L, Colagrande L, et al. Regression of left ventricular hypertrophy after aortic valve replacement for aortic stenosis with different valve substitutes. J Thorac Cardiovasc Surg 1998;116: Silberman S, Shaheen J, Merin O, et al. Exercise hemodynamics of aortic prostheses: Comparison between stentless bioprostheses and mechanical valves. Ann Thorac Surg 2001;72: Castro LJ, Arcidi JM, Jr., Fisher AL, Gaudiani VA. Routine enlargement of the small aortic root: A preventive strategy to minimize mismatch. Ann Thorac Surg 2002;74:31-36; discussion Kon ND, Cordell AR, Adair SM, Dobbins JE, Kitzman DW. Aortic root replacement with the Freestyle stentless porcine aortic root bioprosthesis. Ann Thorac Surg 1999;67: ; discussion Gulbins H, Florath I, Ennker J. Cerebrovascular events after stentless aortic valve replacement during a 9-year follow-up period. Ann Thorac Surg 2008;86: Kobayashi J. Stentless aortic valve replacement: An update. Vasc Health Risk Manage 2011;7: Dumesnil JG, Honos GN, Lemieux M, Beauchemin J. Validation and applications of indexed aortic prosthetic valve areas calculated by Doppler echocardiography. J Am Coll Cardiol 1990;16: Dumesnil JG, Yoganathan AP. Valve prosthesis hemodynamics and the problem of high transprosthetic pressure gradients. Eur J Cardiothorac Surg 1992;6(Suppl.1):S34-S37; discussion S Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position, and its prevention. J Am Coll Cardiol 2000;36: Permanyer E, Estigarribia AJ, Ysasi A, Herrero E, Semper O, Llorens R. St. Jude Medical Trifecta aortic valve perioperative performance in 200 patients. Interact Cardiovasc Thorac Surg 2013;17: Hanke T, Charitos EI, Paarmann H, Stierle U, Sievers HH. Haemodynamic performance of a new pericardial aortic bioprosthesis during exercise and recovery: Comparison with pulmonary autograft, stentless aortic bioprosthesis and healthy control groups. Eur J Cardiothorac Surg 2013;44:e295-e Wendt D, Thielmann M, Plicht B, et al. The new St. Jude Trifecta versus Carpentier-Edwards Perimount Magna and Magna Ease aortic bioprosthesis: Is there a hemodynamic superiority? J Thorac Cardiovasc Surg 2014;147:
Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationHemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves
Hemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves Speaker's name: I have the following potential conflicts of interest to report: Proctorship for Medtronic Agenda Failure modes
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationQUANTIFICATION AND PREVENTION TECHNIQUES OF PROSTHESIS-PATIENT MISMATCH
QUANTIFICATION AND PREVENTION TECHNIQUES OF PROSTHESIS-PATIENT MISMATCH 1,2 Radu A. SASCĂU 3 Cristina OLARIU 1,2 Cristian STĂTESCU 1 Internal Medicine Department, Gr.T.Popa University of Medicine and Pharmacy,
More informationProsthetic valve dysfunction: stenosis or regurgitation
Prosthetic valve dysfunction: stenosis or regurgitation Jean G. Dumesnil MD, FRCP(C), FACC, FASE(Hon) Quebec Heart and Lung Institute, Québec, Québec No disclosures Possible Causes of High Gradients in
More informationPatient/prosthesis mismatch: how to evaluate and when to act?
Patient/prosthesis mismatch: how to evaluate and when to act? Svend Aakhus, MD, PhD Oslo University Hospital, Norway Disclosures: No conflict of interest Types of aortic valve prostheses (AVR) Mechanical
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More informationManagement of Difficult Aortic Root, Old and New solutions
Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult
More informationProsthesis-Patient Mismatch or Prosthetic Valve Stenosis?
EuroValves 2015, Nice Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis? Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE FESC Canada Research Chair in Valvular Heart Diseases Université LAVAL Disclosure
More informationCase. 15-year-old boy with bicuspid AV Severe AR with moderate AS. Ross vs. AVR (or AVP)
Case 15-year-old boy with bicuspid AV Severe AR with moderate AS Ross vs. AVR (or AVP) AMC case 14-year-old boy with bicuspid AV Severe AS with mild AR Body size Bwt: 55 kg, Ht: 154 cm, BSA: 1.53 m 2 Echocardiography
More informationValve prosthesis-patient mismatch (PPM) was first defined
Impact of Valve Prosthesis-Patient Mismatch on Short-Term Mortality After Aortic Valve Replacement Claudia Blais, BSc; Jean G. Dumesnil, MD; Richard Baillot, MD; Serge Simard, MS; Daniel Doyle, MD; Philippe
More informationPPM: How to fit a big valve in a small heart
PPM: How to fit a big valve in a small heart Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC King Abdulaziz Cardiac Centre National Guard Health Affairs Riyadh, Saudi Arabia GHA meeting Muscat
More informationSOLO SMART. The smart way to return to life. Native-like performance now with stented-like implantability
SOLO SMART TM The smart way to return to life Native-like performance now with stented-like implantability MANY PATIENTS NEED SUPERIOR HEMODYNAMIC PERFORMANCE TO RETURN TO THEIR NORMAL LIFESTYLE. 2 SOLO
More informationThe impact of prosthesis patient mismatch after aortic valve replacement varies according to age at operation
Editor s choice Scan to access more free content 1 Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, Maryland, USA 2 Division of Cardiac Surgery, University of Ottawa Heart Institute,
More informationClinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis
CLINICS 2012;67(1):55-60 DOI:10.6061/clinics/2012(01)09 CLINICAL SCIENCE Clinical predictors of prosthesis-patient mismatch after aortic valve replacement for aortic stenosis Luis M. Astudillo, I Orlando
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co-Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationReverse left atrium and left ventricle remodeling after aortic valve interventions
Reverse left atrium and left ventricle remodeling after aortic valve interventions Alexandra Gonçalves, Cristina Gavina, Carlos Almeria, Pedro Marcos-Alberca, Gisela Feltes, Rosanna Hernández-Antolín,
More informationPatient prosthesis mismatch after mitral valve replacement: Myth or reality?
Patient prosthesis mismatch after mitral valve replacement: Myth or reality? Pasquale Totaro, MD, a and Vincenzo Argano, MD b Objective: Determining the risk of patient prosthesis mismatch after mitral
More informationImpact of Prosthesis-Patient Mismatch on Long-Term Survival After Aortic Valve Replacement
Journal of the American College of Cardiology Vol. 53, No. 1, 9 9 by the American College of Cardiology Foundation ISSN 735-197/9/$36. Published by Elsevier Inc. doi:1.116/j.jacc.8.9.22 Valvular Heart
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More information25 different brand names >44 different models Sizes mm
Types of Prosthetic Valves BIOLOGIC STENTED Porcine xenograft Pericardial xenograft STENTLESS Porcine xenograft Pericardial xenograft Homograft (allograft) Autograft PERCUTANEOUS MECHANICAL Bileaflet Single
More informationCARDIACSURGERY TODAY. Commentary and Analysis on Advances in the Surgical Treatment of Cardiac Disease
VOLUME 1 NUMBER 2 23 CARDIACSURGERY TODAY Commentary and Analysis on Advances in the Surgical Treatment of Cardiac Disease EDITORS-IN-CHIEF Robert W Emery, St Paul, MN, USA Francesco Musumeci, Rome, Italy
More informationStentless aortic valves. Current aspects
Endorsed by proceedings in Intensive Care Cardiovascular Anesthesia EXPERT OPINION HSR Proceedings in Intensive Care and Cardiovascular Anesthesia 2012; 4(2): 77-82 Stentless aortic valves. Current aspects
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationDoppler echocardiography is currently the
Doppler Echocardiography of 119 Normal-functioning St Jude Medical Mitral Valve Prostheses: A Comprehensive Assessment Including Time-velocity Integral Ratio and Prosthesis Performance Index* Joseph F.
More informationORIGINAL ARTICLE. Thorsten Hanke a, *, Efstratios I. Charitos a,, Hauke Paarmann b, Ulrich Stierle a and Hans-H. Sievers a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery (2013) 1 7 doi:10.1093/ejcts/ezt367 ORIGINAL ARTICLE Haemodynamic performance of a new pericardial aortic bioprosthesis during exercise and recovery: comparison
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationExperience with 500 Stentless Aortic Valve Replacements
Experience with 500 Stentless Aortic Valve Replacements Dimitrios C. Iliopoulos, MD Cardiac Surgeon Ass. Professor of Surgery University of Athens, School of Medicine I declare no conflict of interest
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationLate incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves
Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves Marc Ruel, MD, MPH a,b Fraser D. Rubens, MD a Roy G. Masters, MD a Andrew L. Pipe, MD a
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationAortic valve replacement and prosthesis-patient mismatch in the era of trans-catheter aortic valve implantation
Gen Thorac Cardiovasc Surg (2016) 64:435 440 DOI 10.1007/s11748-016-0657-9 CURRENT TOPICS REVIEW ARTICLE Aortic valve replacement and prosthesis-patient mismatch in the era of trans-catheter aortic valve
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationTAVR: Echo Measurements Pre, Post And Intra Procedure
2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationThe implantation of bioprostheses is the preferred. Influence of Prosthesis Patient Mismatch on Diastolic Heart Failure After Aortic Valve Replacement
Influence of Prosthesis Patient Mismatch on Diastolic Heart Failure After Aortic Valve Replacement Shahab Nozohoor, MD, Johan Nilsson, MD, PhD, Carsten Lührs, MD, Anders Roijer, MD, PhD, and Johan Sjögren,
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationIn Vitro Two-Dimensional Echocardiographic Imaging of a Stented Porcine Bioprosthetic Valve: The Bent Strut Artifact
C 2008, the Author Journal compilation C 2008, Wiley Periodicals, Inc. DOI: 10.1111/j.1540-8175.2008.00753.x In Vitro Two-Dimensional Echocardiographic Imaging of a Stented Porcine Bioprosthetic Valve:
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationInfluence of patient gender on mortality after aortic valve replacement for aortic stenosis
Influence of patient gender on mortality after aortic valve replacement for aortic stenosis Jennifer Higgins, MD, W. R. Eric Jamieson, MD, Osama Benhameid, MD, Jian Ye, MD, Anson Cheung, MD, Peter Skarsgard,
More informationA Practical Approach to Prosthetic Valves
A Practical Approach to Prosthetic Valves Bonita Anderson DMU (Cardiac), MApplSc (Med Ultrasound), ACS, AMS, FASE https://doi.org/10.1161/circulationaha.108.778886 Disclosures None 1 Know the Product Know
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationProf. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM
The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationTissue vs Mechanical What s the Data??
Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationEmergency Intraoperative Echocardiography
Emergency Intraoperative Echocardiography Justiaan Swanevelder Department of Anaesthesia, Glenfield Hospital University Hospitals of Leicester NHS Trust, UK Carl Gustav Jung (1875-1961) Your vision will
More informationImpact of Valve Prosthesis-Patient Mismatch on Left Ventricular Mass Regression Following Aortic Valve Replacement
Impact of Valve Prosthesis-Patient Mismatch on Left Ventricular Mass Regression Following Aortic Valve Replacement Giordano Tasca, MD, Federico Brunelli, MD, Marco Cirillo, MD, Margherita DallaTomba, MD,
More informationTranscatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis and Small Aortic Annulus
Journal of the American College of Cardiology Vol. 58, No. 10, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.026
More informationReally Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients?
Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients? David H. Adams, MD Cardiac Surgeon-in-Chief Mount Sinai Health System Marie Josée and Henry R. Kravis Professor and
More informationHow Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
More informationPROSTHETIC VALVE BOARD REVIEW
PROSTHETIC VALVE BOARD REVIEW The correct answer D This two chamber view shows a porcine mitral prosthesis with the typical appearance of the struts although the leaflets are not well seen. The valve
More informationTranscatheter valve-in-valve implantation for degenerated surgical bioprostheses
Review Article Transcatheter valve-in-valve implantation for degenerated surgical bioprostheses Dale J. Murdoch, John G. Webb Centre for Heart Valve Innovation, St. Paul s Hospital, Vancouver, Canada Contributions:
More informationDISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.
Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? G. Burkhard Mackensen, MD, PhD, FASE Professor & Chief, Division of Cardiothoracic Anesthesia, Department of Anesthesiology
More informationLate haemodynamic performance and survival after aortic valve replacement with the Mosaic bioprosthesis
Interactive CardioVascular and Thoracic Surgery 19 (2014) 756 762 doi:10.1093/icvts/ivu238 Advance Access publication 12 July 2014 ORIGINAL ARTICLE ADULTCARDIAC Late haemodynamic performance and survival
More informationTrifecta vs. Magna for Aortic Valve Replacement. Differences in Clinical Outcome and Valve Hemodynamics
Circ J 2018; 82: 2767 2775 doi: 10.1253/circj.CJ-18-0744 ORIGINAL ARTICLE Cardiovascular Surgery Trifecta vs. Magna for Aortic Valve Replacement Differences in Clinical Outcome and Valve Hemodynamics Naoki
More informationNew Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology
New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor Cardiothoracic Radiology Disclosure I have no disclosure pertinent to this presentation.
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Director, Interventional Cardiology Research, Beaumont Health System Associate Professor of Medicine,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/28521 holds various files of this Leiden University dissertation Author: Katsanos, Spyridon Title: Outcomes of transcatheter aortic valve implantation Issue
More informationPercutaneous Therapy for Calcific Mitral Valve Disease
31 st Annual State of the Art Echocardiography San Diego, CA February 18, 2018 5:00 5:15 PM 15 min Percutaneous Therapy for Calcific Mitral Valve Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive
More informationAortic valve replacement in predominant aortic stenosis: What is an appropriate size valve?
IJTCVS Joshi et al 141 Aortic valve replacement in predominant aortic stenosis: What is an appropriate size valve? Kishore Joshi, M.Ch., Sachin Talwar, M.Ch., Devagourou Velayoudham, M.Ch., Arkalgud Sampath
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationEight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis
Eight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis Neal D. Kon, MD,* Robert D. Riley, MD, Sandy M. Adair, RN, Dalane W. Kitzman, MD, and A. Robert
More informationComprehensive Echo Assessment of Aortic Stenosis
Comprehensive Echo Assessment of Aortic Stenosis Smonporn Boonyaratavej, MD, MSc King Chulalongkorn Memorial Hospital Bangkok, Thailand Management of Valvular AS Medical and interventional approaches to
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationEffect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival
Effect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival Sukumaran K. Nair, FRCS (C Th), Gauraang Bhatnagar, MBBS, Oswaldo Valencia, MD, and Venkatachalam Chandrasekaran,
More informationSurgical aortic valve replacement (AVR) is the established
The Effect of Surgical and Transcatheter Aortic Valve Replacement on Mitral Annular Anatomy Mathieu Vergnat, MD,* Melissa M. Levack, MD,* Benjamin M. Jackson, MD, Joseph E. Bavaria, MD, Howard C. Herrmann,
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationAssessment of the St. Jude Medical Regent Prosthetic Valve by Continuous-Wave Doppler. and dobutamine stress echocardiography
Assessment of the St. Jude Medical Regent Prosthetic Valve by Continuous-Wave Doppler and Dobutamine Stress Echocardiography Akira Sezai, MD, PhD, Yuji Kasamaki, MD, PhD, Keisuke Abe, RMS, Mitsumasa Hata,
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationTranscatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital,
Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital, Oslo, Norway Aortic regurgitation Prevalence in Framingham
More informationTEE guided TAVR using BASILICA technique in patient with stenotic Freestyle aortic bioprosthesis
TEE guided TAVR using BASILICA technique in patient with stenotic Freestyle aortic bioprosthesis Zuyue Wang MD Associate professor, Georgetown University School of Medicine MedStar Heart and Vascular Institute
More informationFavorable Results in Patients with Small Size CarboMedics Heart Valves in the Aortic Position
Favorable Results in Patients with Small Size CarboMedics Heart Valves in the Aortic Position Kazuhito Imanaka, MD, Shinichi Takamoto, MD, and Akira Furuse, MD 2 Hemodynamic performance of the CarboMedics
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationMichigan Society of Echocardiography 30 th Year Jubilee
Michigan Society of Echocardiography 30 th Year Jubilee Stress Echocardiography in Valvular Heart Disease Moving Beyond CAD Karthik Ananthasubramaniam, MD FRCP (Glas) FACC FASE FASNC Associate Professor
More informationLate secondary TR after left sided heart disease correction: is it predictibale and preventable
Late secondary TR after left sided heart disease correction: is it predictibale and preventable Gilles D. Dreyfus Professor of Cardiothoracic surgery Nath J, et al. JACC 2004 PREDICT Incidence of secondary
More informationTitle of image and video article Sub-Acute Leaflet Thrombosis: A Reversible Cause of Aortic Stenosis
Page 1 of 5 Title of image and video article Sub-Acute Leaflet Thrombosis: A Reversible Cause of Aortic Stenosis Authors Athina Chasapi, Adam Hobbs, Theodore Velissaris & Benoy N Shah. Wessex Cardiac &
More informationAortic valve replacement: is porcine or bovine valve better?
Interactive CardioVascular and Thoracic Surgery Advance Access published December 4, 2012 Interactive CardioVascular and Thoracic Surgery (2012) 1 13 doi:10.1093/icvts/ivs447 BEST EVIDENCE TOPIC Aortic
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationAortic Stenosis: Spectrum of Disease, Low Flow/Low Gradient and Variants
Aortic Stenosis: Spectrum of Disease, Low Flow/Low Gradient and Variants Martin G. Keane, MD, FASE Professor of Medicine Lewis Katz School of Medicine at Temple University Basic root structure Parasternal
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationThe Edge-to-Edge Technique f For Barlow's Disease
The Edge-to-Edge Technique f For Barlow's Disease Ottavio Alfieri, Michele De Bonis, Elisabetta Lapenna, Francesco Maisano, Lucia Torracca, Giovanni La Canna. Department of Cardiac Surgery, San Raffaele
More informationECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction
Role of Stress Echo in Valvular Heart Disease ECHO HAWAII January 15 19, 2018 Kenya Kusunose, MD, PhD, FASE Tokushima University Hospital Japan Not only ischemia! Cardiomyopathy Prosthetic Valve Diastolic
More informationStainless Steel. Cobalt-chromium
Sapien is better than Corevalve! Raj R. Makkar, MD Associate Director, Cedars-Sinai Heart Institute Associate Professor, UCLA School of Medicine, Los Angeles Eberhard Grube: Pioneer in the field of TAVR
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationCarpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years
Surgery for Acquired Cardiovascular Disease Carpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, Robert T. Miyagishima,
More informationLong-term mortality is increased in patients after aortic valve replacement
Bakhtiary et al Surgery for Acquired Cardiovascular Disease Stentless bioprostheses improve postoperative coronary flow more than stented prostheses after valve replacement for aortic stenosis Farhad Bakhtiary,
More informationHemodynamic Assessment. Assessment of Systolic Function Doppler Hemodynamics
Hemodynamic Assessment Matt M. Umland, RDCS, FASE Aurora Medical Group Milwaukee, WI Assessment of Systolic Function Doppler Hemodynamics Stroke Volume Cardiac Output Cardiac Index Tei Index/Index of myocardial
More informationEchocardiographic variables associated with mitral regurgitation after aortic valve replacement for aortic valve stenosis
The Egyptian Heart Journal (2013) 65, 135 139 Egyptian Society of Cardiology The Egyptian Heart Journal www.elsevier.com/locate/ehj www.sciencedirect.com ORIGINAL ARTICLE Echocardiographic variables associated
More informationStent valve implantation in conventional redo aortic valve surgery to prevent patient prosthesis mismatch
Interactive CardioVascular and Thoracic Surgery 24 (2017) 319 323 doi:10.1093/icvts/ivw397 Advance Access publication 31 December 2016 ADULT CARDIAC Cite this article as: Ferrari E, Franciosi G, Clivio
More informationComments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic
Para-ValvularRegurgitation post TAVR: Predict, Prevent, Quantitate, Manage Linda D. Gillam, MD, MPH, FACC, FASE Chair, Department of Cardiovascular Medicine Morristown Medical Center/Atlantic Health System
More informationTreatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques
Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques Pablo Codner, Abid Assali, Hanna Vaknin-Assa, Katia Orvin, Ram Sharony, Leor Perl, Gabriel Greenberg, Marina Kupershmidt,
More informationLate failure of transcatheter heart valves: An open question
Late failure of transcatheter heart valves: An open question A comparison with surgically implanted bioprosthetic heart valves. A. Rashid The Cardiothoracic Centre Liverpool, UK. Conflict of Interest Statement
More informationAlthough mitral valve replacement (MVR) is no longer the surgical
Surgery for Acquired Cardiovascular Disease Ruel et al Late incidence and predictors of persistent or recurrent heart failure in patients with mitral prosthetic valves Marc Ruel, MD, MPH a,b Fraser D.
More informationTransapical Transcatheter Aortic Valve Implantation in the Presence of a Mitral Prosthesis
Journal of the American College of Cardiology Vol. 58, No. 7, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.023
More information